top of page

Free Biopharma Daily Stock Updates - 02/09/22

$XBI $97.26 | +4.65%

 

Covid Updates

$IGMS +9.4% IGM Biosciences Advances Novel Antibody IGM-6268 Into Clinical Trials for the Treatment and Prevention of COVID-19. source



Pipeline Updates

$TSHA +3.4% TAYSHA GENE THERAPIES ANNOUNCES POSITIVE SAFETY DATA FROM UT SOUTHWESTERN-SPONSORED CLINICAL TRIAL FOR THE TREATMENT OF CLN7 BATTEN DISEASE AT 18TH ANNUAL WORLDSYMPOSIUM source


$PHAT +4.5% Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD) source


$RGNX +1.5% REGENXBIO PRESENTS POSITIVE INITIAL DATA FROM PHASE I/II TRIAL OF RGX-111 FOR THE TREATMENT OF SEVERE MPS I AT 18TH ANNUAL WORLDSYMPOSIUM™ 2022 source


$RGNX +1.5% REGENXBIO Presents Additional Positive Interim Data from Phase I/II Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at 18th Annual WORLDSymposium™ 2022. source


$ADIL +1.7% Adial Pharmaceuticals Announces Positive In Vivo Data for Purnovate’s PNV-5032 as a Potential Treatment for Asthma. source


$APVO +5.6% Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update. source


$SMMT +3.3% Summit Therapeutics Announces Postponement of Its Planned Rights Offering. source


$FDMT +0.3% 4D Molecular Therapeutics Announces Updated Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease at the 18th Annual WORLDSymposium. source


$AVRO -6.3% AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis. source


$GMDA +16.8% Gamida Cell Initiates Rolling Submission of Biologics License Application for Omidubicel. source


$APTX +9.8% Aptinyx Hosts Virtual Portfolio Review Event to Showcase NYX-2925 in Chronic Pain and Provide Update on Clinical Development Programs. source


$HGEN +2.5% Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France. source



Business Updates

$AGLE -3.0% Aeglea BioTherapeutics Announces Proposed Public Offering source


$VERU +6.2% Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%. source


$ZSAN -48.6% Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants. source

 

Posted by FS/JM

0 comments
bottom of page